Abstract
Mutation in the p53 gene is the most frequently found genetic abnormality in human tumors, resulting in increased resistance to chemo- and radiotherapy (1,2). The underlying rationale for p53-mediated cancer gene therapy is to restore the ability of p53 mutant tumors to undergo apoptosis. When the wild-type p53 gene is delivered into tumor cells of various origins by adenoviral vector, the cells become more sensitive to cisplatin and radiation therapy (3). In addition, adenovirus expressing p53 is a great laboratory tool for the determination of function, for conveniently producing large quantities of p53 protein, and for determining the effect of p53 on cellular gene expression using microarray technology (4).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Roth, J. A., Swisher, S. G., and Meyn, R. E. (1999) p53 tumor suppressor gene therapy for cancer. Oncology (Huntingt) 13, 148–154.
Roth, J. A., Grammer, S. F., Swisher, S. G., Nemunaitis, J., Merritt, J., and Meyn, R. E., Jr. (2000) Gene replacement strategies for treating non-small cell lung cancer. Semin. Radiat. Oncol. 10, 333–342.
Broaddus, W. C., Liu, Y., Steele, L. L., et al. (1999) Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction. J. Neurosurg. 91, 997–1004.
Maxwell, S. A. and Davis, G. E. (2000) Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. Proc. Natl. Acad. Sci. USA 97, 13,009–13,014.
Berkner, K. L. and Sharp, P. A. (1983) Generation of adenovirus by transfection of plasmids. Nucleic Acids Res. 11, 6003–6020.
Gluzman, Y., Reichl, H., and Solnick, D. (1982) Helper-free adenovirus type-5 vectors, in Eukaryotic Viral Vectors (Gluzman, Y., ed.), Cold Spring Harbor Press, Cold Spring Harbor, NY, pp. 187–192.
Gerard, R. D. and Meidell, R. S. (1995) Adenovirus vectors, in DNA Cloning—A Practical Approach: Mammalian Systems, (Rickwood, D. and Hanes, B. D., eds.), IRL Press, Oxford, UK, pp. 285–306.
Hitt, M. M., Bett, A. J., Addison, C. L., Prevec, L., and Graham, F. L. (1995) Techniques for human adenovirus vector construction and characterization, in: Methods in Molecular Genetics (Adolph, K. W., ed.), Academic Press, San Diego, pp. 13–30.
Johnson, D. C., Ghosh-Choudhury, G., Smiley, J. R., Fallis, L., and Graham, F. L. (1988) Abundant expression of herpes simplex virus glycoprotein gB using an adenovirus vector. Virology 164, 1–14.
Bett, A. J., Prevec, L., and Graham, F. L. (1993) Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67, 5911–5921.
Gorziglia, M. I., Kadan, M. J., Yei, S., et al. (1996) Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70, 4173–4178.
Gao, G. P., Yang, Y., and Wilson, J. M. (1996) Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70, 8934–8943.
Zhang, W. W. (1999) Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6, 113–138.
Kruyt, F. A. and Curiel, D. T. (2002) Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum. Gene Ther. 13, 485–495.
Crouzet, J., Naudin, L., Orsini, C., et al. (1997) Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc. Natl. Acad. Sci. USA 94, 1414–1419.
Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., and Mehtali, M. (1996) Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70, 4805–4810.
He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. (1998) A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509–2514.
Chen, P. L., Chen, Y. M., Bookstein, R., and Lee, W. H. (1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science 250, 1576–1580.
Maizel, J. V., Jr., White, D. O., and Scharff, M. D. (1968) The polypeptides of adenovirus I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115–125.
Shabram, P. W., Giroux, D. D., Goudreau, A. M., et al. (1997) Analytical anionexchange HPLC of recombinant type-5 adenoviral particles. Hum. Gene Ther. 8, 453–465.
Hanahan, D. (1983) Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166, 557–580.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Holmes, M., Rosenberg, E., Valerie, K. (2003). Adenovirus Expressing p53. In: Deb, S., Deb, S.P. (eds) p53 Protocols. Methods in Molecular Biology, vol 234. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-408-5:1
Download citation
DOI: https://doi.org/10.1385/1-59259-408-5:1
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-1-58829-106-6
Online ISBN: 978-1-59259-408-5
eBook Packages: Springer Protocols